RedHill Biopharma (RDHL) Asset Writedowns and Impairment (2017 - 2023)

RedHill Biopharma (RDHL) has reported Asset Writedowns and Impairment for 5 consecutive years, with $60.0 million the latest figure, recorded in Q1 2023.

• On a quarterly basis, Asset Writedowns and Impairment rose 3649.22% year-over-year to $60.0 million in Q1 2023; TTM through Mar 2023 was $64.4 million, a 302.54% increase from a year earlier, with the FY2022 full-year figure at $6.0 million, down 62.93% from the prior year.
• Asset Writedowns and Impairment was $60.0 million for Q1 2023 at RedHill Biopharma, up from $1.5 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $60.0 million in Q1 2023 and troughed at $1.1 million in Q1 2020.
• A 4-year average of $6.9 million and a median of $1.8 million in 2021 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment slumped 85.88% in 2022 and jumped 3649.22% in 2023, its largest moves.
• Over 4 years, Asset Writedowns and Impairment stood at $2.1 million in 2020, then jumped by 417.28% to $10.7 million in 2021, then tumbled by 85.88% to $1.5 million in 2022, then soared by 3856.82% to $60.0 million in 2023.
• The last three Asset Writedowns and Impairment figures came in at $60.0 million (Q1 2023), $1.5 million (Q4 2022), and $1.6 million (Q3 2022), per Business Quant data.